Interleukin-11 (IL-11) upregulation activates the ERK-AMPK-mTORC1 axis, accelerating cellular senescence and metabolic dysfunction. Age-associated IL-11 overexpression in adipose tissue, liver, and skeletal muscle correlates strongly with frailty progression, mitochondrial decay, and tissue fibrosis, aging hallmarks observed in both murine models and human.
Fig. 1 Removal of IL-11 improves health and extends mouse lifespan by up to 24%. (Naito AT, et al., 2010)
CD BioSciences specializes in helping clients develop anti-aging drugs targeting IL-11, with lead candidates demonstrating efficacy in slowing aging and promoting longevity.
Types of Anti-Aging Drugs Targeting IL-11 We Can Develop
Anti-aging antibodies targeting IL-11
Anti-IL-11 antibody candidates represent a potential strategy in lifespan extension. CD BioSciences has extensive experience in designing and developing high-affinity monoclonal antibodies specifically targeting IL-11 with high specificity and efficacy. We offer a range of services to help clients identify whether these antibodies inhibit the action of IL-11 and block IL-11/IL-11Rα interaction, which is known to contribute to fibrosis and inflammation in the aging process.
High-affinity peptide inhibitors of IL-11 signaling
High-affinity peptide inhibitors represent another innovative approach to modulating IL-11 signaling. Our company assists clients in developing these peptide inhibitors, focusing on optimization for their potency and stability. These peptides can disrupt the interaction between IL-11 and its receptor, thereby blocking downstream signaling pathways that lead to aging-related cellular changes.
Targeting IL-11 in Slowing Aging and Promoting Longevity
To effectively study the effects of the IL-11 signaling pathway on aging, we offer a variety of aging models, including cellular senescence, natural aging, and genetically modified animal models.
- We help clients evaluate the impacts of anti-aging drugs targeting IL-11 on cell viability, apoptosis, and senescence. Our expert team helps clients quantify IL-11 mRNA and protein levels in senescent cells compared to non-senescent controls using techniques such as RT-qPCR, ELISA, or Western blotting. We offer reliable services to investigate downstream signaling pathways activated by IL-11 in senescent cells, such as JAK-STAT, MAPK, and PI3K-Akt.
- We support the collection of tissues from mice, rats, or C. elegans at different ages (young, middle-aged, old) and measuring IL-11 mRNA and protein levels using RT-qPCR, ELISA, or immunohistochemistry. Our scientists then help clients analyze the correlation of IL-11 expression with aging-related physiological and functional decline, such as reduced muscle strength, cognitive impairment, or organ dysfunction.
Targeting IL-11 in Aging-Related Diseases
CD BioSciences offers comprehensive services for drug development targeting IL-11 in aging-related diseases, such as fibrosis, cancers, and sarcopenia. Our services span target validation, biomarker identification, drug discovery, and preclinical studies. We provide specialized solutions to evaluate the therapeutic potential of drug candidates in aging-related disease models and to determine whether the drugs can extend lifespan, delay age-related diseases, or improve physiological functions.
Recent research has highlighted that IL-11 is a crucial target in developing effective anti-aging therapeutics. By partnering with CD BioSciences, clients can access tailored solutions that address the unique challenges of developing anti-aging drugs targeting IL-11. If you are interested in our services, please feel free to contact us or make an online inquiry.
References
- Ahmad O, Haris M. Inhibiting IL11: a novel approach to turning back the clock. Immun Ageing, 2024, 21 (1): 71.
- O'Loghlen A. IL-11 as a master regulator of ageing. Nat Rev Mol Cell Biol, 2024, 25 (12): 956.
- Widjaja AA, et al. Inhibition of IL-11 signalling extends mammalian healthspan and lifespan. Nature, 2024, 632 (8023): 157-165.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
